Clinical Trial Update: Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating radiotherapy in combination with QL1706, TAS-102 and bevacizumab for metastatic colorectal cancer; the study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Jinan Central Hospital | Conditions: mCRC | Phase 2 | Status: NOT_YET_RECRUITING